Expert Interview
A Second Look: Discussing the results from part 1 of the ongoing ESSENCE trial of semaglutide at 2.4 mg for adult patients with MASH and moderate to advanced liver fibrosis (stage 2 or 3)
Ticker(s): NVOInstitution: Self-Employed
- double board-certified in Internal Medicine and Gastroenterology/Hepatology, practicing in New York City.
- familiar with the Phase 3 trials (U-EXCEL, U-EXCEED and/or U-ENDURE) evaluating RINVOQ in adult patients with moderately to severely active Crohn's disease
- not yet prescribed Rinvoq for this patient group yet
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
